Patent ID: 11896717
Assignee: INCYTE CORPORATION
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 0:
1. An oral sustained release dosage form comprising:
ruxolitinib phosphate, and
a means for sustained release of the ruxolitinib phosphate,
wherein the ruxolitinib phosphate is present in the dosage form in an amount ranging from 10 mg to 60 mg on a free base basis,
wherein the dosage form is suitable for oral administration,
wherein the administration of the dosage form results in a ratio of mean peak to plasma concentration (Cmax) to mean 12-hour plasma concentration (C12h) of ruxolitinib of 10 or less, and
wherein the administration of the dosage form to a human results in a mean half-life (t1/2) of from 3.5 hours to 11 hours.